small nuclear ribonucleoprotein polypeptide C pseudogene 19Genealiases: []
Q-omics provides the consensus-scored SNRPCP19 profile across patient tissues and cancer cell-line models. SNRPCP19 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SNRPCP19 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, SNRPCP19 RNA expression shows 9,653 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight MESO, KICH, and LAML as cancer lineages where SNRPCP19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNRPCP19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNRPCP19 survival associations across molecular data types. SNRPCP19 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNRPCP19 RNA expression–survival associations across cancer types. High SNRPCP19 expression shows unfavorable associations in MESO, UVM, THCA, KIRC and LAML, but favorable associations in UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SNRPCP19 RNA expression.
This table summarizes SNRPCP19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SNRPCP19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNRPCP19 shows lower tumor expression in KICH and KIRC and higher tumor expression in STAD, HNSC, UCEC and THCA. The KICH box plot shows higher SNRPCP19 RNA expression in normal versus tumor tissue (log2 FC = −0.322, t-test p = .009).
This table shows molecular features associated with SNRPCP19 in patient tissues and cancer cell lines. In patient samples, SNRPCP19 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
